Home Dialysis Focus Relavo is developing a novel infection-prevention device for peritoneal dialysis at-home treatment, presenting a clear near-term opportunity to partner with home healthcare providers, dialysis clinics, and patient support programs seeking safer home-based therapies.

Small Team Advantage With a lean team and early-stage funding, Relavo may be receptive to pilot programs, co-development, or strategic partnerships that accelerate regulatory approval, clinical validation, and market entry through joint ventures or sponsored trials.

Infection Prevention Proposition The core value proposition centers on reducing peritoneal dialysis infections, a compelling differentiator for clinicians, insurers, and patient advocacy groups; this can translate into collaboration with hospital systems and payers interested in lowering complication costs.

Funding and Revenue Gap Current revenue is minimal and funding exists but is modest; sales opportunities may revolve around securing grants, government programs, or corporate partnerships with larger medical device players seeking to expand infection-control portfolios.

Competitive Positioning Relavo sits in a market with large players and extensive networks (e.g., Baxter, Medtronic, Fresenius); a pathway for sales is to align with these ecosystems via strategic collaborations, distribution agreements, or integrative solutions that complement existing dialysis care workflows.